NCT05315687 is a Phase 2 clinical trial of Y-90 SIR-Spheres in Anatomic Stage IV Breast Cancer AJCC v8, sponsored by Emory University.

Who is sponsoring NCT05315687?

NCT05315687 is sponsored by Emory University.

What drugs are being tested in NCT05315687?

Interventions in NCT05315687: Y-90 SIR-Spheres, Yttrium-90 Microsphere Radioembolization, Systemic Therapy.

What condition does NCT05315687 study?

NCT05315687 studies Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver, Prognostic Stage IV Breast Cancer AJCC v8.

Is NCT05315687 still recruiting?

NCT05315687 is currently withdrawn. Last updated 19 January 2024.

Last reviewed 2024-01-19 · How we verify

NCT05315687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Withdrawn Phase 2 Last updated 19 January 2024

What this trial tests

Phase 2 trial testing Y-90 SIR-Spheres in Anatomic Stage IV Breast Cancer AJCC v8. Withdrawn.

Timeline

17 August 2022

Primary endpoint
31 July 2025

31 July 2025

Quick facts

Lead sponsor	Emory University
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	17 August 2022
Primary completion	31 July 2025
Estimated completion	31 July 2025
Sites	1 location across United States

Drugs / interventions tested

Y-90 SIR-Spheres
Yttrium-90 Microsphere Radioembolization
Systemic Therapy — full drug profile →

Conditions studied

Anatomic Stage IV Breast Cancer AJCC v8 — all drugs for Anatomic Stage IV Breast Cancer AJCC v8 →
Metastatic Breast Carcinoma — all drugs for Metastatic Breast Carcinoma →
Metastatic Carcinoma in the Liver — all drugs for Metastatic Carcinoma in the Liver →
Prognostic Stage IV Breast Cancer AJCC v8 — all drugs for Prognostic Stage IV Breast Cancer AJCC v8 →

Sponsor

Emory University

Who can join

18 and older, any sex, with Anatomic Stage IV Breast Cancer AJCC v8 or Metastatic Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies the effects of radioembolization with yttrium Y-90 works as a 2nd or 3rd line therapy for treating patients with breast cancer that has spread to the liver (metastatic to the liver). Yttrium Y-90 radioembolization is a therapy that injects radioactive particles directly into an artery that feeds liver tumors to cut off their blood supply.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Overview of Ongoing Clinical Trials on Radioembolization.
Fabritius MP, Ricke J. · · 2022 · cited 7× · PMID 36184696 · DOI 10.1007/s00270-022-03270-4
Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90).
Wu R, Gogineni K, Meisel J, Szabo S, et al · · 2022 · cited 2× · PMID 36008574 · DOI 10.1007/s00270-022-03254-4

Verify or expand the search:

Other recruiting trials for Anatomic Stage IV Breast Cancer AJCC v8

Currently open trials in the same condition.

NCT07137416 — Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H · Phase 1 · recruiting
NCT06860815 — Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br · Phase 2 · recruiting
NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting
NCT06434064 — Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan · Phase 2 · recruiting
NCT06502691 — [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Ca · Phase 1, PHASE2 · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05315687 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 19 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05315687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing